MedTrace Logo

Tornier Perform™ Reversed Monopost Study

NCT07764614 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-08-14

No results posted yet for this study

Summary

This study is a Multi-center, Prospective Follow-up, Non-significant risk, Post-Market Clinical Follow-Up (PMCF) study to Evaluate the Safety and Effectiveness of the Tornier Perform™ Reversed MonoPost System.

Conditions

  • Non-inflammatory Degenerative Joint Disease
  • Rhematoid Arthritis
  • Correction of Functional Deformity
  • Fracture of the Humeral Head
  • Traumatic Arthritis
  • Revision of the Devices if Sufficient Bone Stock Remains

Interventions

DEVICE

Tornier Perform™ Reversed MonoPost

The Commercially available Tornier Perform™ Reversed MonoPost Glenoid is intended to replace the glenoid part of the scapulohumeral joint as part of a reverse shoulder prosthesis.

Sponsors & Collaborators

  • Stryker Trauma and Extremities

    lead INDUSTRY

Principal Investigators

  • Rebecca Gibson · Stryker Trauma & Extremities

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-28
Primary Completion
2030-12-30
Completion
2031-08-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07764614 on ClinicalTrials.gov